查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2018837

生物醫學植入市場：按類型、材料和應用分類－2026-2032年全球市場預測

Biological Implants Market by Type, Material, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，生物植入市場價值將達到 499.1 億美元，到 2026 年將成長到 609.1 億美元，到 2032 年將達到 2003.9 億美元，複合年成長率為 21.96%。

主要市場統計數據
基準年 2025 499.1億美元
預計年份：2026年 609.1億美元
預測年份 2032 2003.9億美元
複合年成長率 (%) 21.96%

本概述考察了生物醫學植入的現狀，重點關注決定其普及和長期永續性的臨床、技術和營運促進因素。

植入領域融合了前沿材料科學、外科創新和不斷發展的法律規範，為醫療保健相關人員帶來了機會和挑戰。生物材料、微型電子裝置和植入式藥物傳輸系統的快速發展拓展了治療應用範圍，同時也引發了人們對長期性能、生物相容性和臨床證據生成等方面的疑問。在臨床實踐中，多學科團隊正在重新定義整形外科、循環系統醫學、牙科、神經科、眼科和脊椎醫學等領域的治療流程，這要求制定綜合產品策略，以兼顧手術流程、患者報告結果和支付方趨勢。

個人化、數位化增強、程序創新和監管加強如何重塑產品開發、臨床引入和供應策略。

由於技術、臨床和政策因素的融合，植入式醫療技術領域正經歷著變革性的轉變。首先，材料科學和製造技術的進步使得患者個體化植入和模組化平台成為可能，從而應對解剖結構的多樣性和疾病進展，將個人化從概念轉變為實踐。其次，微創和影像導引手術正在拓展適應症並縮短恢復時間，使價值主張從單純的設備成本轉向整個治療過程中的療效。第三，透過植入感測器、遠端監測和預測分析實現的數位化增強，能夠進行持續的性能評估和早期療育，從而將上市後監管框架從定期檢查轉變為即時管理。

評估 2025 年美國關稅措施對零件採購、製造地和採購實務的營運和策略影響。

美國2025年實施的關稅政策為植入式醫療設備的製造商、供應商和經銷商帶來了一系列複雜的考量，影響直接採購成本和更廣泛的供應鏈決策。在零件層面，某些進口原料關稅的提高給依賴海外採購的特殊合金、電子元件和成品模組的醫療設備帶來了價格上漲壓力。為此，許多供應商迅速啟動了成本透明化計劃，並與供應商重新談判合約條款，以保護利潤率並維持臨床試驗點的供應。同時，一些製造商加快了對替代供應商的認證，並擴大了關鍵零件的在地採購，以降低貿易政策變化帶來的風險。

細分分析突顯了從整形外科到眼科植入物等不同植入類別的開發、監管和商業化策略的差異。

對植入分類的詳細分析揭示了不同的創新路徑、監管考慮和臨床應用模式，這些都需要在產品開發和商業化方面採取個人化的策略。整形外科植入類別包括關節重建、骨合成和創傷固定。關節重建又細分為髖關節置換、膝關節置換和肩關節置換，每種關節置換都有其獨特的手術流程和植入生命週期考量。骨合成分為骨板和骨螺釘，創傷固定則涵蓋外固定器、髓內釘以及鋼板和螺釘，每個子類別都指明了特定的材料和機械性能要求，這些要求會影響研發重點。

全球主要地區在管理體制、報銷結構和資本投資方面的差異如何影響臨床導入和商業化選擇？

區域趨勢持續影響著製造商和醫療保健系統的優先事項，不同地理市場的監管、報銷和臨床應用模式也各不相同。在美洲，臨床實務高度重視實證創新和流程效率，支付方也越來越要求提供可驗證的療效和真實世界的臨床績效指標作為報銷依據。在該地區運營的製造商優先投資於完善的上市後監測系統、與綜合醫療保健網路建立合作關係以及開展臨床醫生培訓，以在注重成本的環境下促進產品應用。

跨國公司的規模與Start-Ups的專業創新相互交匯，形成競爭環境：夥伴關係、平台策略和有針對性的臨床差異化。

植入醫療器材領域的競爭格局涵蓋了從成熟的跨國醫療設備製造商到敏捷的臨床階段Start-Ups，形成了一個充滿活力的環境，規模、監管專業知識和專業創新都至關重要。大型公司繼續利用其廣泛的產品系列、強大的臨床網路和完善的品管系統來支援複雜的銷售週期和全球監管申報。這些公司優先考慮生命週期管理、模組化平台策略以及旨在拓展臨床適應症和整合數位醫療能力的策略夥伴關係關係。

公司應實施切實可行的策略和營運措施，以增強韌性，加快在臨床環境中的採用，並確保與監管機構和支付方的合作。

產業領導者必須將洞察轉化為可執行的步驟，以增強韌性、加速部署並保障病患安全，同時保持商業性可行性。首先，繪製關鍵供應鏈節點圖，核實高風險組件二級供應商的合格，並實施透明的成本和前置作業時間管理系統，以降低政策變更和物流中斷帶來的風險。其次，透過設計可操作的臨床試驗和真實世界數據 (RWE) 項目，投資產生符合支付方終點的臨床證據，以證明功能性結果、再入院率和長期設備性能的改善。第三，在產品設計中優先考慮模組化和可升級性，以擴大臨床有效性並實現迭代改進，而無需完全更換。

整合臨床、監管、供應鏈和從業人員視角的研究途徑，確保了全面且檢驗的知識。

本分析的基礎研究結合了對監管文件、同行評審的臨床文獻、專利和公開醫療設備註冊資訊的系統性審查，以及來自臨床醫生、採購經理、監管專家和生產企業高管的針對性專家見解。主要活動包括與多學科執業外科醫生、醫療設備製造商的品質和監管負責人以及負責植入物流的供應鏈經理進行結構化訪談和研討會。次要研究涉及對每種醫療設備的臨床試驗註冊數據、監管指導文件和上市後監測總結的分析，以全面了解其安全性和性能趨勢。

透過整合將醫療設備創新、證據產生和營運韌性連結起來的策略重點，我們能夠帶來永續的臨床和系統效益。

生物醫學植入正進入一個技術多樣性和系統層面考量決定最終產品優劣和患者獲益的關鍵階段。個人化材料、數位化監測和手術創新技術的融合，正在重新定義價值，使其從以設備為中心的特性轉向以綜合護理結果為導向的治療。協調平台設計、臨床證據策略和自適應製造的機構，不僅能夠更有效地應對當前的政策和採購壓力，還能透過顯著改善患者功能和提升護理效率，為永續應用開闢新途徑。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：生物醫學植入市場：按類型分類

  • 自體移植
  • 同種異體移植
  • 異質骨移植

第9章：生物醫學植入市場：依材料分類

  • 膠原蛋白蛋白
  • 聚合物材料
  • 組織起源
  • 混合/生物複合材料

第10章：生物醫學植入市場：依應用領域分類

  • 整形外科植入
  • 心血管植入
  • 植入
  • 顱顏和顎顏面植入

第11章：生物醫學植入市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章：生物醫學植入市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章：生物醫學植入市場：按國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國生物醫學植入市場

第15章：中國生物醫學植入市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • Alphatec Spine, Inc.
  • Auto Tissue Berlin GmbH
  • Baxter International, Inc.
  • Becton, Dickinson and Company
  • BioPolymer GmbH & Co. KG
  • Boston Scientific Corporation
  • Citagenix Inc.
  • Conmed Corporation
  • CryoLife, Inc.
  • Edwards Lifesciences Corporation
  • Globus Medical, Inc.
  • Integra LifeSciences Corporation
  • Johnson & Johnson
  • Medical Device Business Services, Inc.
  • Medtronic plc
  • RTI Surgical, Inc.
  • Sanara MedTech, Inc.
  • Smith & Nephew plc
  • Stryker Corporation
  • Surgenex LLC
  • TissueTech, Inc.
  • Zimmer Biomet Holdings, Inc.
Product Code: MRR-ED54C46E8D5E

The Biological Implants Market was valued at USD 49.91 billion in 2025 and is projected to grow to USD 60.91 billion in 2026, with a CAGR of 21.96%, reaching USD 200.39 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 49.91 billion
Estimated Year [2026] USD 60.91 billion
Forecast Year [2032] USD 200.39 billion
CAGR (%) 21.96%

Framing the contemporary biological implants landscape with clinical, technological, and operational drivers that determine adoption and long-term viability

The field of biological implants sits at the intersection of advanced materials science, surgical innovation, and evolving regulatory oversight, creating both opportunity and complexity for healthcare stakeholders. Rapid advances in biomaterials, miniaturized electronics, and implantable drug delivery are extending therapeutic reach while simultaneously raising questions around long-term performance, biocompatibility, and clinical evidence generation. At the clinical interface, multidisciplinary teams are redefining treatment algorithms across orthopedics, cardiovascular care, dentistry, neurology, ophthalmology, and spinal medicine, demanding integrated product strategies that account for procedural workflow, patient-reported outcomes, and payer dynamics.

Operationally, manufacturers and providers are navigating tighter supply chain expectations, heightened scrutiny over post-market surveillance, and rising expectations for cybersecurity in connected devices. Technological convergence-where sensors, AI-driven diagnostics, and adaptive stimulation meet established implant platforms-is accelerating the pace of innovation but also requiring deeper cross-functional collaboration. As early adopters demonstrate clinical and economic value, procurement, clinical, and regulatory stakeholders must coordinate to translate device-level advances into scalable care pathways that prioritize safety, reimbursement viability, and equitable patient access.

How personalization, digital augmentation, procedural innovation, and regulatory tightening are reshaping product development, clinical adoption, and supply strategies

The landscape for implantable medical technologies is undergoing transformative shifts driven by converging technological, clinical, and policy forces. First, personalization is moving from concept to practice as materials science and manufacturing advances enable patient-specific implants and modular platforms that accommodate anatomical variability and evolving disease presentations. Second, minimally invasive and image-guided procedures are expanding indications and shortening recovery times, shifting value conversations from device cost alone to total episode-of-care outcomes. Third, digital augmentation-through sensors embedded in implants, remote monitoring, and predictive analytics-enables continuous performance assessment and earlier interventions, thereby reframing post-market surveillance from periodic checks to real-time stewardship.

In parallel, regulatory frameworks are adapting to these changes by emphasizing robust clinical evidence, lifecycle management, and cybersecurity controls for networked devices. Supply chains are also recalibrating; providers and manufacturers are balancing globalization with the need for onshore capabilities to ensure continuity of critical components. These shifts are influencing investment priorities, where capital increasingly favors platforms that offer interoperable ecosystems, modular upgrades, and demonstrable improvements in patient-centered outcomes. Consequently, organizations that integrate clinical insight, regulatory foresight, and manufacturing flexibility will be best positioned to capture clinical trust and operational resilience.

Assessing the operational and strategic consequences of the 2025 United States tariff measures on component sourcing, manufacturing footprints, and procurement behaviors

The tariff environment in the United States introduced in 2025 has created a complex set of considerations for manufacturers, providers, and distributors of implantable devices, affecting both direct procurement costs and broader supply chain decisions. At the component level, duties on certain imported inputs have increased the price pressure for devices that rely on specialized alloys, electronic components, and finished modules sourced overseas. In response, many suppliers initiated rapid cost-transparency programs and renegotiated supplier terms to protect margin and preserve clinical access. Simultaneously, some manufacturers accelerated qualifications of alternative suppliers and increased local sourcing for critical components to reduce exposure to trade policy volatility.

Beyond direct cost impacts, the tariff stance influenced strategic choices around manufacturing footprint and inventory posture. Several organizations revisited localization strategies, evaluating near-shore and onshore manufacturing investments to mitigate future policy risk and shorten replenishment lead times. These investments often required parallel adjustments to quality systems, regulatory filings, and workforce training, creating near-term implementation challenges but improving operational resilience long term. Clinicians and procurement teams observed that pricing dynamics prompted more stringent value assessments and extended contract negotiations, encouraging stronger collaboration between clinical evidence teams and commercial functions to preserve access while maintaining sustainable business models.

Segment-specific analysis highlighting how implant subcategories from orthopedics to ocular devices demand distinct development, regulatory, and commercialization strategies

A nuanced segmentation of implant classes reveals differentiated innovation pathways, regulatory considerations, and clinical adoption patterns that demand tailored strategies for product development and commercialization. The orthopedic implant category encompasses joint replacement, osteosynthesis, and trauma fixation; joint replacement further differentiates into hip, knee, and shoulder replacement subdomains, each with distinct surgical workflows and implant lifecycle considerations. Osteosynthesis divides into bone plates and bone screws, while trauma fixation spans external fixators, intramedullary nails, and plates and screws, with each subcategory exhibiting specific material and mechanical performance requirements that influence R&D priorities.

Cardiovascular implants include heart valves, stents, and vascular grafts; heart valves are split between mechanical and tissue options, and stents are categorized as bare metal or drug-eluting, with divergent regulatory paths and evidence expectations. Dental implants are reviewed across endosseous, subperiosteal, and zygomatic implants; endosseous implants further separate into blade form and root form, each addressing different anatomical constraints and restoration philosophies. Spinal implants cover disc replacement, spinal fixation, and spinal fusion devices; spinal fixation is further detailed as plates and screws and rods, while spinal fusion devices include bone graft substitutes and cages, signaling varied biological integration and device-host interactions. Neurological implants span deep brain stimulators, spinal cord stimulators, and vagal nerve stimulators; deep brain stimulators are examined in adaptive and fixed-rate formats, and spinal cord stimulators in paddle and percutaneous configurations, reflecting differences in precision therapy and implantation complexity. Ocular implants concentrate on intraocular lenses and retinal implants; intraocular lenses are profiled as monofocal, multifocal, and toric, and retinal implants as epiretinal and subretinal, each demanding specialized surgical techniques and patient selection criteria.

Understanding these segment-specific nuances enables tailored clinical development plans and targeted reimbursement strategies. For example, modular platforms and upgrade paths are more relevant in joint replacement and spinal systems, whereas miniaturization and power management are central to neurological and retinal implants. Regulatory submission strategies, post-market evidence generation, and clinician training programs must align with the mechanical, biological, and procedural characteristics unique to each segmentation node to optimize adoption and long-term safety outcomes.

How divergent regulatory regimes, reimbursement frameworks, and capacity investments across major global regions influence clinical adoption and commercialization choices

Regional dynamics continue to drive differentiated priorities for manufacturers and health systems, with geographic markets exhibiting distinct regulatory, reimbursement, and clinical adoption patterns. In the Americas, clinical practice strongly favors evidence-backed innovations and procedural efficiency, and payers increasingly condition reimbursement on demonstrable outcomes and real-world performance metrics. Manufacturers operating in this region prioritize robust post-market surveillance systems, partnerships with integrated delivery networks, and investments in clinician education to support uptake in cost-conscious environments.

Across Europe, Middle East & Africa, regulatory harmonization and cross-border approvals influence go-to-market sequencing and clinical trial design, while diverse payer models require adaptable pricing and access strategies. The region presents a mixture of centralized procurement programs in some jurisdictions and highly decentralized hospital purchasing in others, so manufacturers must balance standardized value dossiers with localized value arguments. In the Asia-Pacific region, rapid technology adoption is coupled with varied regulatory maturity and an emphasis on scalable manufacturing and cost competitiveness. Several markets in this region are investing heavily in domestic capacity building and local clinical evidence generation, which creates both collaboration opportunities and competitive pressures for global firms that seek to establish sustainable, regionally relevant supply and evidence strategies.

Competitive dynamics where multinational scale and focused startup innovation converge, driving partnerships, platform strategies, and targeted clinical differentiation

The competitive landscape for implant technologies reflects a spectrum from established multinational device manufacturers to agile clinical-stage startups, creating a dynamic environment where scale, regulatory expertise, and focused innovation all matter. Large corporate players continue to leverage broad product portfolios, deep clinical networks, and extensive quality systems to support complex sales cycles and global regulatory submissions. These firms prioritize lifecycle management, modular platform strategies, and strategic partnerships that expand clinical indications and integrate digital health capabilities.

At the same time, smaller specialized companies and academic spinouts are driving breakthroughs in materials, sensing, and adaptive stimulation, often securing first-mover clinical differentiation in narrow indications. These innovators typically pursue targeted clinical proof points and strategic co-development or licensing arrangements to accelerate market entry. Investors and corporate development teams are focusing on collaborations that complement core strengths-such as pairing advanced biomaterials with established surgical instruments or attaching software-enabled analytics to proven implant platforms-to reduce time to clinical adoption and expand the perimeter of value for providers and patients. Across the competitive set, organizations that synchronize regulatory strategy, evidence generation, and commercial engagement will sustain differentiation and patient trust.

Practical strategic and operational measures companies should implement to enhance resilience, accelerate clinical adoption, and secure regulatory and payer alignment

Industry leaders must translate insight into practical steps that bolster resilience, accelerate adoption, and protect patient safety while preserving commercial viability. First, map critical supply chain nodes and qualify secondary suppliers for high-risk components, while implementing transparent cost and lead-time governance to reduce exposure to policy shifts and logistical disruption. Second, invest in clinical evidence generation that aligns with payer endpoints by designing pragmatic trials and real-world evidence programs that demonstrate improvements in functional outcomes, readmissions, and longitudinal device performance. Third, prioritize modularity and upgradeability in product design to extend clinical relevance and enable iterative improvements without wholesale replacement.

Additionally, integrate cybersecurity and software lifecycle management into device development from the earliest design phases, and establish clear pathways for post-market surveillance that leverage remote monitoring data where permitted. Pursue strategic alliances with health systems for co-developed value pathways and provider education programs to accelerate procedural adoption. Finally, cultivate policy engagement and regulatory intelligence capabilities to anticipate compliance changes and to align development timelines with evolving approval requirements, thereby reducing friction in market entry and scaling.

Integrated research approach combining clinical, regulatory, supply chain, and expert practitioner inputs to ensure comprehensive and validated findings

The research underpinning this analysis combined systematic review of regulatory documentation, peer-reviewed clinical literature, patents, and public device registries with targeted expert input from clinicians, procurement leaders, regulatory specialists, and manufacturing executives. Primary engagements included structured interviews and workshops with practicing surgeons across multiple specialties, quality and regulatory leaders within medical device firms, and supply chain managers responsible for implant logistics. Secondary research encompassed analysis of clinical trial registries, guidance documents issued by regulatory authorities, and device-specific post-market surveillance summaries to ensure a comprehensive view of safety and performance trends.

Data were triangulated by cross-referencing clinical outcomes, device technical specifications, and regulatory pathways to validate thematic findings. Limitations of the methodology include variability in public data completeness across regions and the proprietary nature of certain supplier contracts, which can constrain visibility into specific cost structures. To mitigate these constraints, qualitative weighting was applied where direct evidence was limited, and all primary inputs were anonymized and consented for use. Ethical standards were observed throughout the research process, with an emphasis on transparency and reproducibility of the analytic approach.

Synthesis of strategic priorities that connect device innovation, evidence generation, and operational resilience to realize durable clinical and system-level benefits

Biological implants are entering a phase where technological plurality and system-level considerations determine winner profiles and patient impact. The confluence of personalized materials, digital monitoring, and procedural innovation is reshaping the value equation from device-centric attributes to integrated care outcomes. Organizations that harmonize platform design, clinical evidence strategies, and adaptive manufacturing will not only navigate current policy and procurement pressures more effectively but will also unlock new avenues for sustainable adoption through demonstrable improvements in patient function and care efficiency.

Looking ahead, collaborators across industry, clinical practice, and policy will need to invest in interoperable ecosystems, transparent post-market evidence frameworks, and agile regulatory engagement to translate device innovation into measurable clinical benefits. The strategic priorities articulated in this summary-supply chain resilience, targeted evidence generation, and platform modularity-provide a pragmatic blueprint for leaders seeking to align innovation with real-world clinical and operational demands. Continued focus on patient-centric outcomes and responsible technology stewardship will be essential to maintaining public trust and ensuring that implantable technologies deliver durable health gains.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biological Implants Market, by Type

  • 8.1. Autografts
  • 8.2. Allografts
  • 8.3. Xenografts

9. Biological Implants Market, by Material

  • 9.1. Collagen-based
  • 9.2. Polymeric Materials
  • 9.3. Tissue-derived
  • 9.4. Hybrid/Bio-composite

10. Biological Implants Market, by Application

  • 10.1. Orthopedic Implants
  • 10.2. Cardiovascular Implants
  • 10.3. Dental Implants
  • 10.4. Craniofacial & Maxillofacial Implants

11. Biological Implants Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Biological Implants Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Biological Implants Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Biological Implants Market

15. China Biological Implants Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Abbott Laboratories
  • 16.6. AbbVie Inc.
  • 16.7. Alphatec Spine, Inc.
  • 16.8. Auto Tissue Berlin GmbH
  • 16.9. Baxter International, Inc.
  • 16.10. Becton, Dickinson and Company
  • 16.11. BioPolymer GmbH & Co. KG
  • 16.12. Boston Scientific Corporation
  • 16.13. Citagenix Inc.
  • 16.14. Conmed Corporation
  • 16.15. CryoLife, Inc.
  • 16.16. Edwards Lifesciences Corporation
  • 16.17. Globus Medical, Inc.
  • 16.18. Integra LifeSciences Corporation
  • 16.19. Johnson & Johnson
  • 16.20. Medical Device Business Services, Inc.
  • 16.21. Medtronic plc
  • 16.22. RTI Surgical, Inc.
  • 16.23. Sanara MedTech, Inc.
  • 16.24. Smith & Nephew plc
  • 16.25. Stryker Corporation
  • 16.26. Surgenex LLC
  • 16.27. TissueTech, Inc.
  • 16.28. Zimmer Biomet Holdings, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOLOGICAL IMPLANTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOLOGICAL IMPLANTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES BIOLOGICAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA BIOLOGICAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY AUTOGRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY AUTOGRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY AUTOGRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ALLOGRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ALLOGRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ALLOGRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY XENOGRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY XENOGRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY XENOGRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY COLLAGEN-BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY COLLAGEN-BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY COLLAGEN-BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY POLYMERIC MATERIALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY POLYMERIC MATERIALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY POLYMERIC MATERIALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TISSUE-DERIVED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TISSUE-DERIVED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY TISSUE-DERIVED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY HYBRID/BIO-COMPOSITE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY HYBRID/BIO-COMPOSITE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY HYBRID/BIO-COMPOSITE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY ORTHOPEDIC IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY CARDIOVASCULAR IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DENTAL IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DENTAL IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY DENTAL IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY CRANIOFACIAL & MAXILLOFACIAL IMPLANTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY CRANIOFACIAL & MAXILLOFACIAL IMPLANTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY CRANIOFACIAL & MAXILLOFACIAL IMPLANTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS BIOLOGICAL IMPLANTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 42. AMERICAS BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. NORTH AMERICA BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. LATIN AMERICA BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 51. EUROPE, MIDDLE EAST & AFRICA BIOLOGICAL IMPLANTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 59. MIDDLE EAST BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. MIDDLE EAST BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. MIDDLE EAST BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 63. AFRICA BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. AFRICA BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AFRICA BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 66. AFRICA BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. ASEAN BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. ASEAN BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. ASEAN BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 75. ASEAN BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. GCC BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GCC BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. GCC BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 79. GCC BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPEAN UNION BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPEAN UNION BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPEAN UNION BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPEAN UNION BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 84. BRICS BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. BRICS BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. BRICS BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 87. BRICS BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 88. G7 BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. G7 BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. G7 BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 91. G7 BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. NATO BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NATO BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. NATO BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 95. NATO BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL BIOLOGICAL IMPLANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. UNITED STATES BIOLOGICAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 98. UNITED STATES BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. UNITED STATES BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 100. UNITED STATES BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. CHINA BIOLOGICAL IMPLANTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 102. CHINA BIOLOGICAL IMPLANTS MARKET SIZE, BY TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. CHINA BIOLOGICAL IMPLANTS MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 104. CHINA BIOLOGICAL IMPLANTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)